作者: Stephan J. Sanders , , Benjamin M. Neale , Hailiang Huang , Donna M. Werling
DOI: 10.1038/S41593-017-0017-9
关键词:
摘要: As technology advances, whole genome sequencing (WGS) is likely to supersede other genotyping technologies. The rate of this change depends on its relative cost and utility. Variants identified uniquely through WGS may reveal novel biological pathways underlying complex disorders provide high-resolution insight into when, where, in which cell type these are affected. Alternatively, cheaper less computationally intensive approaches yield equivalent insights. Understanding the role rare variants noncoding gene-regulating pilot projects will be critical determining two extremes best represents reality. With large cohorts, well-defined risk loci, a compelling need understand biology, psychiatric have play preliminary assessment. Whole Genome Sequencing for Psychiatric Disorders Consortium integrate data 18,000 individuals with disorders, beginning autism spectrum disorder, schizophrenia, bipolar major depressive along over 150,000 controls.